ENERGY & COMMERCE DRUG BENEFIT DEBATE MOVING ON TO MEDICARE EXCLUSION AUTHORITY; BREAKTHROUGH COUNCIL OUT, DINGELL SAYS: BIO WARY OF WYDEN CRADA BILL
Executive Summary
House Energy & Commerce Committee's consideration of pharmaceutical benefits under the Clinton health care reform plan is moving on to modification of the Medicare drug exclusion authority after Chairman Dingell (D-Mich.) promised his support for deletion of the Advisory Council on Breakthrough Drugs.